Peter Kyle said he wants the likes of Wegovy and Mounjaro to be 'widely used' and made 'available to everyone from every background'.

Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under Medicare and Medicaid. This plan aims to provide millions of Americans suffering ...

Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Eli Lilly's pill, orforglipron, is a step closer to becoming the first needle-free alternative in the booming market for weight loss drugs.

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.